The Clinical Study On The Prevention And Control Of Pu Yi Race-related Acute Respiratory Infections With Yupingfengsan

ObjectiveThe use of etanercept for the treatment of rheumatoid arthritis patients prophylactic treatment Yupingfengsan particles, by observing the changes in the number and frequency of patients with influenza-associated immune indicators for Yupingfeng,cd4, cd8, cd4/cd8valuee. Discussion Yupingfengsan benefit tournament on Cape prevention of acute respiratory infeections related to the internal mechanism for the prevention and control of biological agents Yupingfengsan provide clinical evidence related adverse reactionsMethodsSelect diagnosed with rheumatoid arthritis and lung deficiency type72patients were randomly divided into two groups:38cases of the treatment group and the control group of34patients.The two groups are routinely applied methotrexate therapy, Experimental group was given Yupingfengsan particles plus etanercept treatment; the control group to etanercept treatment; Treatment group given yupinfeng powder particles and a blunt, a bag each time, three times a day, for3months; Follow-up three months after treatment, both groups recorded the frequency of colds, the impact of the two groups before and after treatment RA disease activity score, and inflammatory immune parameters related indicators.Resultsâ‘ After treatment, the treatment group, the frequency of acute respiratory infections was significantly lower than the control group, there was a significant difference (t=2.7280, p<0.01)differences.â‘¡Before treatment, the treatment group and the control group cd4, cd8, cd4/cd8value by t test, the difference was not statistically significant (p>0.05). After treatment, among the same group cd4,cd8,cd4/cd8value comparison, the differences were statistically significant (p<0.05). After treatment cd4, cd4/cd8was significantly lower than the control group, there was a significant difference (p<0.01) differences. After treatment, cd8value comparison between the two groups, the difference was not statistically significant (p>0.05).â‘¢Before treatment, the treatment group and the control group vas, das28, esr, crp values by t test, the difference was not statistically significant (p>0.05). After treatment, vas, das28, esr, crp contrast between the same group, the differences were statistically significant (p<0.05). After treatment, the two vas, das28, esr, crp value comparison, the difference was not statistically significant (p>0.05).ConclusionsYupingfengsan particles can reduce cd4,cd4/cd8, regulate the immune function of patients, can effectively prevent the etanercept-related acute respiratory infections.